scRADAR: Dissecting intratumoral drug response heterogeneity at single-cell resolution via mechanism-guided prototype routing
PLOS Computational Biology · 26.06.2026 · 22 (6) · e1014392
DOI: 10.1371/journal.pcbi.1014392 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Computational Biology, online erschienen am 26.06.2026. Verfasst von Ren Qi und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Computer Science and Technology, Beijing Institute of Technology, Beijing, China. Hauptthemen laut MEDLINE: Single-Cell Analysis, Neoplasms, Antineoplastic Agents. Die Arbeit nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Beijing Natural Science Foundation, Zhongguancun Academy.
Abstract (Originalsprache)
Precision oncology requires resolving intratumoral heterogeneity to identify drug-resistant cell states associated with treatment failure and relapse. Although single-cell RNA sequencing enables characterization of heterogeneous resistance-associated states, single-cell drug-response phenotype prediction remains challenging because of sparsity, noise, class imbalance, and limited mechanistic interpretability. Here, we present scRADAR (Response Analysis via Drug-Aware Routing), a mechanism-guided prototype routing framework for predicting and interpreting drug-response phenotypes at single-cell resolution. Rather than relying on cell-line–anchored transfer learning, scRADAR learns directly from labeled single-cell cohorts. The framework integrates metabolic and signaling pathway activities to form a dual-view cellular representation, conditions pathway embeddings on drug mechanisms through feature-wise linear modulation, and uses sparse prototype routing to decompose predictions into interpretable response archetypes. Across nine independent cohorts, scRADAR showed strong predictive performance and consistent cross-cohort behavior, particularly under imbalanced settings. Post hoc attribution analyses highlighted candidate TGF-β-associated epithelial-to-mesenchymal transition signatures in Erlotinib-associated Resistant-labeled states and cytoskeletal/metabolic response-associated signatures in BET-inhibitor-associated Resistant-labeled states. These results suggest that scRADAR provides an interpretable framework for single-cell drug-response phenotype prediction and for generating hypotheses about resistance-associated programs from heterogeneous tumor transcriptomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Computer Science and Technology, Beijing Institute of Technology, Beijing, China.
- Zhongguancun Academy, Beijing, China.
- Department of Biology, Lomonosov Moscow State University, Moscow, Russia.
- SMBU-MSU-BIT Joint Laboratory on Bioinformatics and Engineering Biology, Shenzhen MSU-BIT University, Shenzhen, Guangdong, China.
ORCID-Profile: Bin Liu
Förderung
- National Natural Science Foundation of China
- Beijing Natural Science Foundation
- Zhongguancun Academy
- Lomonosov Moscow State University
Zitieren
APA
Qi, R., Teng, W., Yang, X., Han, P., Shaytan, A. K., & Liu, B. (2026). scRADAR: Dissecting intratumoral drug response heterogeneity at single-cell resolution via mechanism-guided prototype routing. PLOS Computational Biology, 22(6), e1014392. https://doi.org/10.1371/journal.pcbi.1014392
Vancouver
Qi R, Teng W, Yang X, Han P, Shaytan AK, Liu B. scRADAR: Dissecting intratumoral drug response heterogeneity at single-cell resolution via mechanism-guided prototype routing. PLOS Computational Biology. 2026;22(6):e1014392. doi:10.1371/journal.pcbi.1014392
BibTeX
@article{Qi2026,
author = {Qi, Ren and Teng, Wenjie and Yang, Xin and Han, Peng and Shaytan, Alexey K and Liu, Bin},
title = {scRADAR: Dissecting intratumoral drug response heterogeneity at single-cell resolution via mechanism-guided prototype routing},
journal = {PLOS Computational Biology},
year = {2026},
volume = {22},
number = {6},
pages = {e1014392},
doi = {10.1371/journal.pcbi.1014392}
}
EUVIMED